Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Cancer Science|January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical OutcomesKinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
JTO Clinical and Research Reports|March 19, 2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter StudyAkito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort studyNao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Emerging Infectious Diseases|June 22, 2022
Chronic Pulmonary Disease Caused by Tsukamurella toyonakaenseTomoki Kuge, Kiyoharu Fukushima, Yuki Matsumoto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2021
IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor ImmunityYasuhiko Suga, Izumi Nagatomo, Yuhei Kinehara, et al.
JCI Insight|April 7, 2022
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancerKentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
International Journal of Molecular Sciences|February 13, 2025
NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular VesiclesMaiko Naito, Yoshito Takeda, Ryuya Edahiro, et al.
Pageof 14